Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2-metastatic breast cancer.

被引：15
|
作者：
Mayer, Erica L.
Wander, Seth Andrew
Regan, Meredith M.
DeMichele, Angela
Forero-Torres, Andres
Rimawi, Mothaffar F.
Ma, Cynthia X.
Cristofanilli, Massimo
Anders, Carey K.
Bartlett, Cynthia Huang
Winer, Eric P.
Burstein, Harold J.
机构：
[1] Dana Farber Canc Inst, Waban, MA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Penn Med Abramson Canc Ctr, Philadelphia, PA USA
[4] Univ Alabama Birmingham, Birmingham, AL USA
[5] Baylor Coll Med, Houston, TX 77030 USA
[6] Washington Univ, Sch Med St Louis, St Louis, MO USA
[7] Northwestern Univ, Robert H Lurie Canc Ctr, Feinberg Sch Med, Chicago, IL USA
[8] Univ N Carolina, Chapel Hill, NC 27515 USA
[9] Pfizer Inc, Collegeville, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS1104
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1104
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2-Metastatic Breast Cancer
    Mayer, Erica L.
    Ren, Yue
    Wagle, Nikhil
    Mahtani, Reshma
    Ma, Cynthia
    DeMichele, Angela
    Cristofanilli, Massimo
    Meisel, Jane
    Miller, Kathy D.
    Jolly, Trevor
    Riley, Elizabeth
    Qamar, Rubina
    Sharma, Priyanka
    Reid, Sonya
    Sinclair, Natalie
    Faggen, Meredith
    Block, Caroline
    Ko, Naomi
    Partridge, Ann
    Chen, Wendy Y.
    Demeo, Michelle K.
    Attaya, Victoria
    Okpoebo, Amanda
    Liu, Yuan
    Gauthier, Eric
    Burstein, Harold
    Regan, Meredith
    Tolaney, Sara
    CANCER RESEARCH, 2023, 83 (05)
  • [2] Palbociclib after CDK inhibitor and endocrine therapy (PACE): A randomized phase II study of fulvestrant versus palbociclib plus fulvestrant, with and without avelumab, for CDK inhibitor pre-treated HR+/HER2-metastatic breast cancer
    Mayer, Erica L.
    Wander, Seth A.
    Regan, Meredith M.
    DeMichele, Angela M.
    Forero, Andres
    Rimawi, Mothaffar F.
    Ma, Cynthia X.
    Cristofanilli, Massimo
    Anders, Carey K.
    Bartlett, Cynthia Huang
    Koehler, Maria
    Winer, Eric P.
    Burstein, Harold J.
    CANCER RESEARCH, 2018, 78 (04)
  • [3] Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pretreated ER+/HER2- Metastatic Breast Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 9 - 10
  • [4] PYTHIA: A phase II study of palbociclib plus fulvestrant for pretreated patients with ER+/HER2-metastatic breast cancer
    Zardavas, D.
    Regan, M.
    Maibach, R.
    Ruepp, B.
    Hiltbrunner, A.
    Blacher, L.
    Gelber, R.
    Gebhart, G.
    Di Leo, A.
    Hilbers, F.
    Colleoni, M.
    Zoppoli, G.
    Bertelli, G.
    Bliss, J.
    Duhoux, F.
    Piccart, M.
    Malorni, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Exploration of ctDNA Dynamics in the PACE Trial: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for HR+/HER2-Metastatic Breast Cancer
    Jeselsohn, Rinath
    Fu, Jingxin
    Ren, Yue
    Mahtani, Reshma
    Ma, Cynthia
    DeMichele, Angela
    Cristofanilli, Massimo
    Meisel, Jane
    Miller, Kathy
    Abdou, Yara
    Riley, Elizabeth
    Qamar, Rubina
    Sharma, Priyanka
    Reid, Sonya
    Ko, Naomi
    Liu, Yuan
    Burstein, Harold
    DeMeo, Michelle
    Tolaney, Sara
    Mayer, Erica
    CANCER RESEARCH, 2024, 84 (09)
  • [6] EFFICACY AND SAFETY PROFILE OF PALBOCICLIB AND FULVESTRANT IN PATIENTS ER+/HER2-METASTATIC BREAST CANCER OF A SINGLE ONCOLOGICAL CENTRE
    Alevizopoulos, Nektarios
    Alexandris, Dimitrios
    Folinas, Konstantinos
    Dimitriadou, Areti
    Pavlakis, Michael
    Kammenou, Helen
    BREAST, 2021, 59 : S63 - S63
  • [7] Frontline Fulvestrant, Palbociclib Combo Is Effective for Endocrine-Sensitive, HR+/HER2-Metastatic Breast Cancer
    不详
    ONCOLOGY-NEW YORK, 2020, 34 (11): : 486 - 486
  • [8] Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
    Arshad, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1491 - S1492
  • [9] The SMILE study: A phase 2 trial of onapristone in combination with fulvestrant for patients with ER+ and HER2-metastatic breast cancer after progression on endocrine therapy and CDK4/6 inhibitors
    Kamaraju, Sailaja
    Fowler, Amy
    Cheng, Chung Yee
    Chaudhary, Lubna N.
    Burfeind, John
    Retseck, Janet
    Tevaarwerk, Amye J.
    Burkard, Mark
    Paplomata, Elisavet
    Parkes, Amanda M.
    Jorns, Julie M.
    Tarima, Sergey
    Yee, Douglas
    Rui, Hallgeir
    Lange, Carol
    Sahmoud, Tarek
    Wisinski, Kari B.
    CANCER RESEARCH, 2022, 82 (04)
  • [10] Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy
    Luc Cabel
    Dan Rosenblum
    Florence Lerebours
    Etienne Brain
    Delphine Loirat
    Mattias Bergqvist
    Paul Cottu
    Anne Donnadieu
    Anne Bethune
    Nicolas Kiavue
    Manuel Rodrigues
    Jean-Yves Pierga
    Marie-Laure Tanguy
    François-Clément Bidard
    Breast Cancer Research, 22
12345